glp-1 agonist indications Can one drug do it all? Reviewing the expanding clinical universe of agonists GLP-1 receptor agonist prescriptions for

21 (UPI) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea

SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms

Lightly pat for absorption AI-generated from the product information

Given the heterogeneity in study populations and the predominance of post hoc analyses, further prospective research is essential to clarify these mechanisms and to evaluate whether personalized, sex-specific approaches to GLP-1 RA therapy could improve obesity treatment outcomes

C.JohnstonE